-
Signature
-
/s/ Tae Sang Yoo, Attorney-in-Fact
-
Issuer symbol
-
BMRN
-
Transactions as of
-
02 May 2025
-
Net transactions value
-
-$2,944
-
Form type
-
4
-
Filing time
-
06 May 2025, 17:07:22 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Hubbard Cristin |
EVP, Chief Commercial Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL |
/s/ Tae Sang Yoo, Attorney-in-Fact |
06 May 2025 |
0002021836 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BMRN |
Common Stock |
Award |
$14,779 |
+273 |
+0.83% |
$54.14 |
32,973 |
30 Apr 2025 |
Direct |
F1 |
| transaction |
BMRN |
Common Stock |
Sale |
$17,723 |
-273 |
-0.83% |
$64.92 |
32,700 |
02 May 2025 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: